Compare Cincinnati Financial Corporation (CINF) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cincinnati Financial Corporation vs Mesoblast Limited — how do they compare? Cincinnati Financial Corporation trades at $172.49 (market cap $26.58B), while Mesoblast Limited trades at $16.75 (market cap $2.21B). The key difference: Cincinnati Financial Corporation is far larger — about 12× Mesoblast Limited's market cap, and Cincinnati Financial Corporation pays a 2.17% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| CINF | MESO | |
|---|---|---|
Market Cap | $26.58B | $2.21B |
Sector | Financials | Technology |
52-Week High | $192.03 | $20.96 |
52-Week Low | $149.79 | $12.88 |
Enterprise Value | $25.71B | $2.21B |
Dividend Yield | 2.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cincinnati Financial (CINF) trades at $172.87, down 0.57% on the day, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 earnings miss ($1.43 vs. $1.84 expected) but maintains robust revenue growth and profitability with a 23.84% net income margin. Cash flow trends show improvement, with 2025 net cash flow reaching $448 million. Analyst consensus remains positive with a $195 price target, though technical indicators suggest near-term pressure.
CINF presents a value opportunity with attractive valuation metrics (P/E 8.18, P/B 1.59) and consistent dividend growth. Key risks include catastrophe losses impacting underwriting results and commercial lines performance. The stock's current technical weakness may offer entry points for long-term investors seeking quality insurance exposure with strong ROE of 21.48%.
MESO trades at $16.82, up 0.84% with bullish technical signals from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144.33% net income margin. Recent developments include positive Phase 3 trial progress and BLA filing for heart failure treatment, supported by analyst consensus leaning bullish with 45% buy ratings.
MESO presents a high-risk, high-reward opportunity with promising commercial traction offset by significant losses. Investment thesis hinges on successful pipeline development and profitability turnaround, while risks include clinical trial outcomes, regulatory approvals, and sustained cash burn requiring careful monitoring of execution milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cincinnati Financial Corporation
Cincinnati Financial Corp is a property and casualty insurance company that generates income through written premiums. A select group of independent agencies actively markets the company's business, home, and automotive insurance within their communities. These agents offer the company's personal lines as well as its standard market, excess, and surplus commercial line policies in many regions in the United States. Cincinnati Financial also offers leasing and financing services. The vast majority of the company's revenue is generated through commercial lines, followed by personal lines.
Read more on CINF →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
